﻿ AE Time to Event
Reports | AE Time to Event

AE Time to Event
The AE Time to Event report screens all adverse events by performing log-rank and Wilcoxon tests between treatment groups. The time to first occurrence of the adverse event is used as the response.
Note: If you run this analysis using data from a blinded study or from a study that has only one ARM, you generate a different set of output. See AE Time to Event (One ARM) for a detailed description
The AE Time to Event report screens all adverse events by performing log-rank and Wilcoxon tests between treatment groups. The time to first occurrence of the adverse event is used as the response.
Report Results Description
Running this report with the Nicardipine sample setting generates the tabbed Results shown below.
Volcano Plots
Presents summary figures for two popular statistical tests for Kaplan-Meier analyses: the Log-Rank and Wilcoxon.
The Volcano Plots section contains the following elements:
 • Two Volcano Plots.
The Y axis represents the -log10(raw p-value) from either the Log-Rank test (left) or the Wilcoxon test (right). In most instances, these two tests coincide. To interpret this axis, consider the following.
1. a p-value of 1 equals 0 on the -log10 scale,
2. a p-value of 0.1 equals 1 on the -log10 scale,
3. a p-value of 0.01 equals 2 on the -log10 scale,
4. a p-value of 0.001 equals 3 on the -log10 scale,
5. a p-value of 0.0001 equals 4 on the -log10 scale.
The X axis represents the maximum computed distance between the two curves, and color indicates which treatment was likely to have the event sooner. For example, Phlebitis occurs at approximately 0.27 on the X axis and is green. This means that at least one time point in the Kaplan-Meier and Hazard Plots, the risk of having this particular event was 27% more likely for Nicardipine versus Placebo.
Events above the dotted red line are considered statistically significant after adjusting for multiple comparisons. Adjustment is applied using the linear step-up method of Benjamini and Hochberg (1995) to control the false discovery rate.
Action Buttons
Action buttons, provide you with an easy way to drill down into your data. The following action buttons are generated by this report:
 • Kaplan-Meier and Hazard Plots: Click to generate individual Kaplan-Meier and hazard curves for selected events. This button is surfaced when Time to first event is specified as the Response Type.
 • Fit Incidence Density Model: Click to fit selected events to a generalized linear model. This button is surfaced when either Incidence density based on first event only or Incidence density based on all events is specified as the Response Type.
General
 • Click to view the associated data tables. Refer to View Data for more information.
 • Click to generate a standardized pdf- or rtf-formatted report containing the plots and charts of selected sections.
 • Click to take notes, and store them in a central location. Refer to Add Notes for more information.
 • Click the Options arrow to reopen the completed report dialog used to generate this output.
 • Click the gray border to the left of the Options tab to open a dynamic report navigator that lists all of the reports in the review. Refer to Report Navigator for more information.
Note: For information about how treatment emergent adverse events (TEAEs) are defined in JMP Clinical, please refer to How does JMP Clinical determine whether an Event Is a Treatment Emergent Adverse Event?..
Report Options
Term Level
The Term Level is determined by the coding dictionary for the Event or Intervention domain of interest, typically these levels follow the MedDRA dictionary. You must indicate how each adverse event is named and the level at which the event is considered. For example, selecting Reported Term reports the event specified by the actual event term as reported in the AE domain.
Treatment or Comparison Variable:
The primary goal of clinical trials is to distinguish treatment effects when reporting and analyzing trial results. Treatments are defined by specific values in the treatment or comparison variables of the CDISC models. These variables are specified in this report using the Treatment or Comparison Variable to Use andTreatment or Comparison Variable options.
Distributions of the specified treatment or comparison variables are shown in the output.
Available variables include Planned, which is selected when the treatments patients received exactly match what was planned and Actual, which is selected when treatment deviates from what was planned.
You can also specify a variable other than the ARM or TRTxxP (planned treatment) or ACTARM or TRTxxA (actual treatment) from the CDISC models as a surrogate variable to serve as a comparator. Finally, you can select None to plot the data without segregating it by a treatment variable.
See Treatment or Comparison Variable to Use, Treatment or Comparison Variable for more information.
By default, all events are included in the analysis. However, you can opt to include only those considered serious. Selecting the Include serious adverse events only option restricts the analysis to those adverse events defined as Serious under FDA guidelines.
Analysis can consider all events or only those that emerge at specific times before, during, or after the trial period. For example, selecting On treatment events as the Event Type includes only those events that occur on or after the first dose of study drug and at or before the last dose of drug (+ the offset for end of dosing).
If you choose to Ignore available treatment emergent flags, the analysis includes all adverse events that occur on or after day 1 of the study.
By default, post-treatment monitoring begins after the patient receives the last treatment. However, you might want to specify an Offset for End of Dosing, increasing the time between the end of dosing and post-treatment monitoring for treatments having an extended half-life.
Check the Treatment end date is equivalent to the start date if the treatment end date (EXTENDTC) is missing from the data. In this case, it is assumed that all treatments were given on the same day and that the treatment start date can be used instead.
By default this report examines the time to the first event as the Response Type, In this analysis, a test of differences of time to first event across treatment groups is conducted using both Log-Rank and Wilcoxon statistics. Alternatively, you can opt to use incidence densities. Incidence densities compare the proportion of occurrences of events across treatment groups. Data for incidence density, based on the first event only, are aggregated to the treatment level whereas data for incidence density based on all events are aggregated to the subject level.
Use the Include events with overall percent occurrence greater than option to specify a threshold for reporting adverse events. Only events that occur above the entered threshold (in terms of overall percent of occurrence) are displayed in the reports. This value is set to 0 by default, so that all adverse event occurrences are included.
Filtering the Data:
Filters enable you to restrict the analysis to a specific subset of subjects and/or adverse events based on values within variables. You can also filter based on population flags (Safety is selected by default) within the study data.
If there is a supplemental domain (SUPPAE) associated with your study, you can opt to merge the non-standard data contained therein into your data.